Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your Child's DNA predict the best ADHD drug?

NCT ID NCT06221358

Knowledge-focused Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study explores whether a child's genetic makeup influences how well they respond to the ADHD medication methylphenidate. Researchers will track symptom changes and side effects in 400 participants aged 6-24 across Western Canada. The goal is to find genetic markers that could one day help personalize ADHD treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
methylphenidate
What this could lead to
If successful, this could help doctors choose the right ADHD medication based on a child's genes, reducing trial-and-error.
What could go wrong
This is an observational study, not a treatment trial. It may not find clear genetic links, and results may not change practice for years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Children and adolescent with primary diagnosis of ADHD (all types), aged 6-24 years.

Ages

6 to 24 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients will be eligible for participation if all the following are true. * Aged 6 - 24 years. * Located in Western Canada (i.e., Alberta, British Columbia, Saskatchewan, Manitoba). * Primary diagnosis of ADHD (all types). * Starting Methylphenidate (excluding immediate release forms) treatment. Exclusion Criteria: Patients will be excluded from participation if any of the following are true. * Co-occurring psychotic, bipolar or eating disorders. * Significant risk of suicide. * An intellectual disability, or diagnosis of autism spectrum disorder (ASD) or tics/Tourette disorders. * Past 12-month high-risk alcohol or substance use defined as monthly or more frequent use. * Psychotherapy or brain stimulation-based therapy initiated within 8 weeks of referral or plans to initiate/change these types of therapies during the study * History of liver or bone marrow (hematopoietic cell) transplant as these events can result in ambiguous genomic results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Attention-deficit/hyperactivity disorder (ADHD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Attention-deficit/hyperactivity disorder (ADHD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Calgary

    RECRUITING

    Calgary, Alberta, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.